◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Rubicon Research Limited (RUBICON) Financial History

Name: Rubicon Research Limited (RUBICON) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - General · DATA UPDATED 2026-09-20

Rubicon Research Limited (RUBICON) operates in the Drug Manufacturers - General industry and is headquartered in Mumbai, India with about 1,290 employees. Its market capitalization is roughly ₹289 billion. In the fiscal year ended 2026-03-31, RUBICON reported ₹17.3B in revenue and ₹2.5B in net income.

Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally.

Interactive charts & full statements →

RUBICON Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31
Total Revenue	₹17.3B	₹12.7B
Gross Profit	₹11.5B	₹8.8B
Operating Income (EBIT)	₹3.6B	₹2.2B
Net Income	₹2.5B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RUBICON Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹5.3B	₹5.1B	₹4.8B	₹3.5B	₹3.6B	—
Gross Profit	₹3.7B	₹3.4B	₹3.2B	₹2.5B	₹2.5B	—
Operating Income (EBIT)	₹1.1B	₹1.1B	₹966M	₹695M	₹628M	—
Net Income	₹848M	₹768M	₹728M	—	₹362M	₹381M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RUBICON Free Cash Flow History

Cash flow	2026-03-31	2025-03-31
Dividends Paid	(₹3M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

RUBICON Balance Sheet History

Balance sheet	2026-03-31	2025-03-31
Total Assets	₹23.3B	—
Total Liabilities	₹10.4B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive RUBICON viewer.

RUBICON Metric Deep Dives

Other Companies in Drug Manufacturers - General

4503 · Astellas Pharma Inc. — JPY 4.27 trillion
4528 · Ono Pharmaceutical Co., Ltd. — JPY 1.12 trillion
4536 · Santen Pharmaceutical Co., Ltd. — JPY 549 billion
GLAXO · GlaxoSmithKline Pharmaceuticals Limited — ₹481 billion
NOVN · Novartis AG — CHF 219 billion
PFIZER · Pfizer Limited — ₹183 billion
MARKSANS · Marksans Pharma Limited — ₹145 billion
1093 · CSPC Pharmaceutical Group Limited — HK$102 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← RUBI All “R” companies RUBYMILLS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.